In vitro screening of neuroprotective activity of Indian medicinal plant Withania somnifera

Singh, Manjeet et Ramassamy, Charles (2017). In vitro screening of neuroprotective activity of Indian medicinal plant Withania somnifera Journal of Nutritional Science , vol. 6 , nº e54. pp. 1-5. DOI: 10.1017/jns.2017.48.

Prévisualisation

PDF - Version publiée Disponible sous licence Creative Commons Attribution Non-commercial Share Alike. Télécharger (327kB) | Prévisualisation

Résumé

Canine cognitive dysfunction (CCD) is an age-dependent neurodegenerative condition characterised by changes in decline in learning and memory patterns. The neurodegenerative features of CCD in ageing dogs and cats are similar to human ageing and Alzheimer's disease (AD). Discovering neuroprotective disease-modifying therapies against CCD and AD is a major challenge. Strong evidence supports the role of amyloid β peptide deposition and oxidative stress in the pathophysiology of CCD and AD. In both the human and canine brain, oxidative damage progressively increases with age. Dietary antioxidants from natural sources hold a great promise in halting the progression of CCD and AD. Withania somnifera (WS), an Ayurvedic tonic medicine, also known as ‘Indian ginseng’ or ashwagandha has a long history of use in memory-enhancing therapy but there is a dearth of studies on its neuroprotective effects. The objective of this study was to investigate whether WS extract can protect against Aβ peptide- and acrolein-induced toxicity. We demonstrated that treatment with WS extract significantly protected the human neuroblastoma cell line SK-N-SH against Aβ peptide and acrolein in various cell survival assays. Furthermore, treatment with WS extract significantly reduced the generation of reactive oxygen species in SK-N-SH cells. Finally, our results showed that WS extract is also a potent inhibitor of acetylcholinesterase activity. Thus, our initial findings indicate that WS extract may act as an antioxidant and cholinergic modulator and may have beneficial effects in CCD and AD therapy. Copyright © The Author(s) 2017 This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type de document:	Article
Mots-clés libres:	Acetylcholinesterase; Acrolein; Amyloid β-peptide; Oxidative stress; Withania somnifera
Centre:	Centre INRS-Institut Armand Frappier
Date de dépôt:	25 mars 2019 19:09
Dernière modification:	25 mars 2019 19:09
URI:	https://espace.inrs.ca/id/eprint/6748

Gestion Actions (Identification requise)

Modifier la notice